Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Lowers Price Target on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion lowered the target of its follow-on offering of stock on Friday after the close of the market.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it will register 4.6 million shares of its common stock at $6.49 per share, raising a maximum of almost $29.9 million.

In January, the company said it planned to register more than 2 million shares at a maximum of $8.22 per share, with plans of raising up to $17.3 million. Less than two weeks ago, it amended its S-1 form to offer 4 million shares at a maximum price of $7.36 per share, which would have brought in up to $33.9 million.

Vermillion also gave Roth Capital Partners, the underwriter on the planned offering, the option to purchase 600,000 shares to cover overallotments, if any.

Last week, the company reported $345,000 in fourth-quarter revenues and $1.2 million in revenues for full-year 2010.

In early Monday trade on the Nasdaq, shares of Vermillion were down 1 percent at $5.51.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.